Comparison · NCT00452530-sae
Apixiban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Apixiban, 2.5 mg BID Plus Placebo vs Enoxaparin, 40 mg QD Plus Placebo: serious adverse events. Trial comparisons, record NCT00452530-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00452530-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.048 | 0.0383 | 0.06 | wilson | |
| Risk in group 2 | 0.0584 | 0.0476 | 0.0713 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0104 | -0.0266 | 0.00573 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.822 | 0.607 | 1.11 | log | |
| Odds ratio, group 1 over group 2 | 0.813 | 0.59 | 1.12 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Apixiban, 2.5 mg BID Plus Placebo than on Enoxaparin, 40 mg QD Plus Placebo | 96.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Apixiban, 2.5 mg BID Plus Placebo | Participants received apixaban, 2.5 mg twice daily (BID), as oral tablets, and matching enoxaparin-placebo injection once daily (QD) | 72 | 1,501 | EG000 |
| Group 2 | Enoxaparin, 40 mg QD Plus Placebo | Participants received enoxaparin, 40 mg QD subcutaneously, and matching apixaban-placebo tablets BID | 88 | 1,508 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- NCT number
- NCT00452530
- Phases
- PHASE3
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2014-05-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00452530?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00452530-sae